Open AccessBaricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Author(s) -
Peter C. Taylor,
Edward Keystone,
Désirée van der Heijde,
Michael E. Weinblatt,
Liliana Morales,
Jaime Reyes Gonzaga,
S. S. Yаkushin,
Taeko Ishii,
Kahaku Emoto,
Scott D. Beattie,
Vineet M. Arora,
C. Gaich,
Terence Rooney,
Douglas Schlichting,
William L. Macias,
Stephanie de Bono,
Yoshiya Tanaka
Publication year - 2017
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1608345
Subject(s) - medicine , adalimumab , rheumatoid arthritis , placebo , antirheumatic agents , dermatology , alternative medicine , pathology
Baricitinib is an oral, reversible inhibitor of the Janus kinases JAK1 and JAK2 that may have therapeutic value in patients with rheumatoid arthritis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom